TransCelerate BioPharma has selected Cognizant to develop a subscription-based platform to help the pharmaceutical industry to bring standardization and consistency to clinical trials.
Assisting in transforming the way clinical sites collaborate with pharmaceutical companies on clinical trials, the Shared Investigator Platform will be built as an industry utility. The important benefit is that pharmaceutical firms can run clinical trials more efficiently and accelerate the development of new medicines.
Cognizant said the new platform will enhance organizational productivity by providing investigators and site staff with a central, single access point to clinical trial information, enhancing accuracy, and reducing study start-up time.
It will also help pharmaceutical companies to improve quality, regulatory compliance, process visibility, and capacity, while reducing investigator efforts related to training, document exchange, and support. In the future, the platform may provide regulators with an efficient electronic audit process and better insight into clinical trials.
Bhaskar Sambasivan, vice president of Cognizant’s Life Sciences practice, said: “Streamlining the clinical trials process will enable TransCelerate’s member companies to speed up drug development and drive innovation in improving patient health.”